You just read:

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer

News provided by

Daiichi Sankyo Company, Limited

Aug 29, 2017, 08:00 ET